Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1.   On continuation of ADT and ARAT switch
2. Systemic therapy options after progression
3. Improper mandated crossover
4. PARP inhibitors in prostate cancer

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Freedland SJ et al. NEJM. 2023;389(16):1453-1465. doi:10.1056/NEJMOA2303974/

2.           de Bono J et al. NEJM. 2020;382(22):2091-2102. doi:10.1056/NEJMOA1911440/

3.           Haslam A, Prasad V. Annals of Oncology. 2018;29(5):1079. doi:10.1093/ANNONC/MDY116

4.           Parker C et al. NEJM. 2013;369(3):213-223. doi:10.1056/NEJMOA1213755/

5.           Khalaf DJ et al. Lancet Oncol. 2019;20(12):1730-1739. doi:10.1016/S1470-2045(19)30688-6

6.           Saad F et al.. J Natl Cancer Inst. 2004;96(11):879-882. doi:10.1093/JNCI/DJH141

7.           Sartor O et al. NEJM. 2021;385(12):1091-1103. doi:10.1056/NEJMOA2107322/

8.           de Wit R et al. NEJM. 2019;381(26):2506-2518. doi:10.1056/NEJMOA1911206/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. The chemotherapy revolution in prostate cancer
2. Role of ARATs in earlier disease states
3. Triple therapy (chemotherapy, ADT, and ARAT)
4. Considerations for frailer patients with indolent disease

 Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Hussain M et al.. J Clin Oncol. 2023;41(20):3595-3607. doi:10.1200/JCO.23.00041

2.           Smith MR et al. NEJM. 2022;386(12):1132-1142. doi:10.1056/NEJMOA2119115/

3.           Fizazi K et al. Lancet. 2022;399(10336):1695-1707. doi:10.1016/S0140-6736(22)00367-1

4.           Sweeney CJ et al. Lancet Oncol. 2023;24(4):323-334. doi:10.1016/S1470-2045(23)00063-3

5.           Wenzel M, et al. Prostate Cancer and Prostatic Diseases 2021 25:2. 2021;25(2):139-148. doi:10.1038/s41391-021-00395-4

6.           Gravis G et al. Lancet Oncol. 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0

7.           James ND et al. NEJM. 2017;377(4):338-351. doi:10.1056/NEJMOA1702900/SUPPL_FILE/

8.           Fizazi K, et al. Lancet Oncol. 2019;20(5):686-700. doi:10.1016/S1470-2045(19)30082-8

9.           James ND et al. Lancet. 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5

10.        Gravis G et al. Lancet Oncol. 2013;14(2):149-158. doi:10.1016/S1470-2045(12)70560-0

11.        Sweeney CJ et al. NEJM. 2015;373(8):737-746. doi:10.1056/NEJMOA1503747/SUPPL_FILE\

12.        James ND et al. The Lancet. 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5

13.        Fizazi K et al. NEJM. 2017;377(4):352-360. doi:10.1056/NEJMOA1704174

14.        Tannock et al. NEJM 2004;351(15):1502-1512. doi:10.1056/NEJMOA040720

15.        Petrylak DP et al.. NEJM. 2004;351(15):1513-1520. doi:10.1056/NEJMOA041318

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Physiology, efficacy and toxicities of androgen deprivation
2. Evidence for adjuvant intervention after definitive surgery or radiation
3. Role of abiraterone in high-risk localized prostate cancer
4. Limited evidence to support definitive salvage approach

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Attard G et al. Lancet. 2022;399(10323):447-460. doi:10.1016/S0140-6736(21)02437-5

2.           Xie W et al. J Clin Oncol. 2017;35(27):3097-3104. doi:10.1200/JCO.2017.73.9987

3.           Bolla M et al.. NEJM. 2009;360(24):2516-2527. doi:10.1056/NEJMOA0810095/

4.           Kishan AU et al. Lancet Oncol. 2022;23(2):304-316. doi:10.1016/S1470-2045(21)00705-1

5.           Bolla M et al. Lancet. 2002;360(9327):103-108. doi:10.1016/S0140-6736(02)09408-4

6.           Bolla M et al.  Lancet Oncol. 2010;11(11):1066-1073. doi:10.1016/S1470-2045(10)70223-0

7.           Bolla M et al. NEJM. 2009;360(24):2516-2527. doi:10.1056/NEJMOA0810095/

8.           Hanks GE et al.  J  Clin Oncol. 2003;21(21):3972-3978. doi:10.1200/JCO.2003.11.023

9.           Bolla M et al. Lancet. 2002;360(9327):103-108. doi:10.1016/S0140-6736(02)09408-4

10.        Huggins C, Hodges C V. CA Cancer J Clin. 1972;22(4):293-297. doi:10.3322/CANJCLIN.22.4.232

11.        Huggins C et al. Arch Surg. 1941;43(2):209-223. doi:10.1001/archsurg.1941.01210140043004

12.        Rosenthal SA et al. J Clin Oncol. 2019;37(14):1159-1168. doi:10.1200/JCO.18.02158

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Background and presentation of prostate Cancer
2. Evidence behind PSA screening and hallmarks of a screening test
3. Staging and risk stratification of Localized Disease
4. Management options and the ProtecT Trial

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.Schroder F et al.  NEJM. 2009; 360(13):1320-1328.  doi: 10.1056/NEJMOA0810084/

2.  Andriole G el al. NEJM.  2009; 360(13):1310-1319.  doi: 10.1056/NEJMOA0810696/

3. Lane J et al.  Lancet.  2014; 15(10):1109-1118. doi: 10.1016/S1470-2045(14)70361-4

4. Hamdy F et al.  NEJM. 2016; 375(15):1415-1424.  doi: 10.1056/NEJMOA1606220

5.  Hamdy F et al. NEJM. 2023; 388(17):1547-1558.  doi: 10.1056/NEJMOA2214122/

6. Ilic D et al.  BMJ. 2018; 362:k3519.  doi:10.1136/BMJ.K3519

7.Maurer T et al.  Nat Rev Urol. 2016;13(4):226-235.   doi: 10.1038/nrurol.2016.26. Epub 2016 Feb 23

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Role for definitive chemotherapy and radiation
2. Controversy on induction chemotherapy
3. Considerations for nasopharyngeal cancer
4. Approach to metastatic HNSCC

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Burtness B et al. J Clin Oncol. 2022;40(21):2321-2332. doi:10.1200/JCO.21.02198

2.           Burtness B et al. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7

3.           Vermorken JB et al. NEJM 2008;359(11):1116-1127. doi:10.1056/NEJMOA0802656

4.           Gibson MK et al. JCO. 2005;23(15):3562-3567. doi:10.1200/JCO.2005.01.057

5.           Zhang L et al. Lancet. 2016;388(10054):1883-1892. doi:10.1016/S0140-6736(16)31388-5

6.           Zhang Y et al. NEJM. 2019;381(12):1124-1135. doi:10.1056/NEJMOA1905287

7.           Gau M et al. Oral Oncol. 2019;95:164-169. doi:10.1016/J.ORALONCOLOGY.2019.06.015

8.           GT W, et al. NEJM. 1991;324(24):1685-1690. doi:10.1056/NEJM199106133242402

9.           Lacas B et al. Radiother Oncol. 2021;156:281. doi:10.1016/J.RADONC.2021.01.013

10.        Bourhis  et al. JCO. 2004;22(14_suppl):5505-5505. doi:10.1200/JCO.2004.22.90140.5505

11.        Gyawali B et al. Cancer Treat Rev. 2016;44:10-16. doi:10.1016/J.CTRV.2016.01.002

12.        Forastiere AA et al. J Clin Oncol. 1992;10(8):1245-1251. doi:10.1200/JCO.1992.10.8.1245

13.        Posner MR et al. NEJM. 2007;357(17):1705-1715. doi:10.1056/NEJMOA070956/

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Anatomy, diagnostic work-up and staging
2. Field cancerization
3. Indications for adjuvant concurrent chemoradiation
4. Evidence to support weekly cisplatin with concurrent radiation

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Bernier J et al. Head Neck. 2005;27(10):843-850. doi:10.1002/HED.20279

2.           Zevallos JP et al. Head Neck. 2021;43(1):108. doi:10.1002/HED.26465

3.           Young A, Okuyemi OT. StatPearls. Published online January 12, 2023. Accessed October 30, 2023. https://www.ncbi.nlm.nih.gov/books/NBK563022/

4.           Kiyota N et al.  J Clin Oncol. 2022;40(18):1980-1990. doi:10.1200/JCO.21.01293

5.           Sharma P et al. J Clin Oncol. 2022;40(16). doi: 10.1200/JCO.2022.40.16_suppl.6004

6.           Cooper JS et al. NEJM. 2004;350(19):1937-1944. doi:10.1056/NEJMOA032646

7.           Bernier J et al. NEJM. 2004;350(19):1945-1952. doi:10.1056/NEJMOA032641

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Presentation, and considerations for regional mesothelioma
2. Systemic therapy options for advanced mesothelioma
3. Corticosteroids for pemetrexed, paclitaxel and docetaxel
4. A quick review on considerations for LCNEC

 Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Peters S et al. Ann Oncol. 2022;33(5):488-499. doi:10.1016/j.annonc.2022.01.074

2.           Baas P et al. Lancet. 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8

3.           Vogelzang NJ et al. J Clin Oncol. 2003;21(14):2636-2644. doi:10.1200/JCO.2003.11.136

4.           Zalcman G, et al. Lancet. 2016;387(10026):1405-1414. doi:10.1016/S0140-6736(15)01238-6

5.           Santoro A, et al. J Thorac Oncol. 2008;3(7):756-763. doi:10.1097/JTO.0B013E31817C73D6

6.           Lindsay CR et al. Br J Cancer 2021;125(9):1210-1216. doi:10.1038/s41416-021-01407-9

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Background on SCLC
2. Approach to treatment by stage
3. Emerging discussion on prophylactic cranial irradiation
4. Brief review of basket and umbrella trials

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Trigo J et al. Lancet Oncol. 2020;21(5):645-654. doi:10.1016/S1470-2045(20)30068-1

2.           O’Brien MER et al. J Clin Oncol. 2006;24(34):5441-5447. doi:10.1200/JCO.2006.06.5821

3.           Rudin CM et al. J Clin Oncol. 2020;38(21):2369-2379. doi:10.1200/JCO.20.00793

4.           Paz-Ares L et al. The Lancet. 2019;394(10212):1929-1939. doi:10.1016/S0140-6736(19)32222-6

5.           Horn L et al NEJM. 2018;379(23):2220-2229. doi:10.1056/NEJMOA1809064/

6.           Lowenbraun S et al. Cancer. 1979;44:406-413. doi:10.1002/1097-0142

7.           Hochstenbag M et al.. J Neurooncol. 2000;48(3):243-248. doi:10.1023/A:1006427407281

8.           Meert AP et al. BMC Cancer. 2001;1(1):1-9. doi:10.1186/1471-2407-1-5/TABLES/4

9.           Fried DB et al.  J Clin Oncol. 2004;22(23):4785-4793. doi:10.1200/JCO.2004.01.178

10.        Pignon JP et al. 2010;327(23):1618-1624. doi:10.1056/NEJM199212033272302

11.        Warde P, Payne D.   J Clin Oncol. 1992;10(6):890-895. doi:10.1200/JCO.1992.10.6.890

12.        Wong AT et al. J Thorac Oncol. 2016;11(2):242-248. doi:10.1016/J.JTHO.2015.10.011

13.        Lu C  et al. Ther Innov Regul Sci. 2021;55(6):1145. doi:10.1007/S43441-021-00315-7

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Refresher on T+N staging for Stage III
2. Evidence for concurrent chemoradiation
3. PACIFIC Trial
4. Encourage cessation regardless of stage of Lung Cancer

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1.           Ajani JA et al.. Ann Oncol. 2013;24(11):2844-2849. doi:10.1093/ANNONC/MDT339

2.           Curran WJ et al. J Natl Cancer Inst. 2011;103(19):1452-1460. doi:10.1093/JNCI/DJR325

3.           Vokes EE, et al. JCO. 2007;25(13):1698-1704. doi:10.1200/JCO.2006.07.3569

4.           Dillman RO et al. NEJM. 1990;323(14):940-945. doi:10.1056/NEJM199010043231403

5.           Daly ME et al. JCO. 2022;40(12):1356-1384. doi:10.1200/JCO.21.02528

6.           Spigel DR et al. JCO. 2022;40(12):1301-1311. doi:10.1200/JCO.21.01308

7.           Antonia SJ et al. NEJM. 2017;377(20):1919-1929. doi:10.1056/NEJMOA1709937

8.           Senan et al. JCO. 2016;34(9):953-962. doi:10.1200/JCO.2015.64.8824

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

1. Background on adjuvant EGFR therapy
2. Discussion of initial and updated results
3. Hazard Ratios and Context
4. When crossover and access limit generalizability


Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.

1.Herbst et al. JCO.  2023;41(10):1830-1840. doi: 10.1200/JCO.22.02186
2.Wu et al. NEJM. 2023;383:1711-1723. doi:10.1056/NEJMoa2027071
3.       Tsuboi et al. NEJM. 2023;389(2):137-147. doi: 10.1056/NEJMoa2304594
4. West and Gyawali. JAMA Oncol. 2021;7(5):677-678. doi:10.1001/jamaoncol.2020.6752
5. Gyawali and West. JCO. 2021;39(3):175-177. doi: 10.1200/JCO.20.01762
6. Prasad. Plenary Session.  “ADAURA OS Results”. Podcast episode published June 8, 2023 
7. Haslan and Prasad. Ann Oncol. 2018; 29(5):1079–1081. doi: 10.1093/annonc/mdy116
8. Tannock et al. JCO.  2023;41(15):2713-2717 doi: 10.1200/JCO.23.00280


 
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology